Home/Pipeline/Novel GLP-1 Receptor Agonist

Novel GLP-1 Receptor Agonist

Metabolic Disorders

Pre-clinical/ClinicalLicensed (Gan & Lee)N/A

Key Facts

Indication

Metabolic Disorders

Phase

Pre-clinical/Clinical

Status

Licensed (Gan & Lee)

Company

Lupin

About Lupin

Lupin is a mission-driven global pharmaceutical company focused on improving access to essential and advanced medicines through the development and commercialization of generic drugs, complex formulations, and biosimilars. Founded in 1968, it has grown into a top-tier generics player with a significant presence in the US, India, and other key markets, underpinned by robust R&D and manufacturing capabilities. Its strategy centers on expanding its complex generics and specialty portfolio, advancing its biosimilars pipeline, and leveraging operational excellence to drive sustainable, long-term growth.

View full company profile

Therapeutic Areas

Multi-Therapeutic Metabolic Central Nervous System Gastroenterology Ophthalmology Respiratory

Other Metabolic Disorders Drugs

Drug	Company	Phase	Status
Undisclosed Metabolic Program	Kallyope	Discovery	Active
Metabolic Disorders Program	Seragon Biosciences	Pre-clinical	Active
PPARγ Program	Micar Innovation	Discovery	Active
Pancreas-Targeting Capsids	rAAVen Therapeutics	Pre-clinical	Active
IVL-001	InVirtuoLabs	Discovery	Active
Amylin Program	Orion Biotechnology	Discovery	Active